Sandeep Mittal
Overview
Explore the profile of Sandeep Mittal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
2579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arya B, Mittal S, Joshi P, Pandey A, Ramirez-Vick J, Gupta G, et al.
Beilstein J Nanotechnol
. 2025 Mar;
16:316-332.
PMID: 40041432
Autophagy is a highly regulated catabolic process by which unnecessary, dysfunctional, or damaged proteins and other cellular components are degraded and recycled to promote cellular differentiation, survival, and development. In...
2.
Abedin M, Michelhaugh S, Mittal S, Berdichevsky Y
Front Bioeng Biotechnol
. 2023 Mar;
11:1150772.
PMID: 36970613
Glioblastoma (GBM) invasiveness and ability to infiltrate deep into the brain tissue is a major reason for the poor patient prognosis for this type of brain cancer. Behavior of glioblastoma...
3.
Chakrapani V, Newman P, Sebastian A, Rawat S, Mittal S, Gupta V, et al.
Sex Reprod Health Matters
. 2022 Dec;
30(1):2144087.
PMID: 36476183
Scant empirical research from Asia has addressed the impact of COVID-19 on sexual minority health. We aimed to explore and understand the impact of COVID-19 on income security, mental health,...
4.
Pandey M, Xiu J, Mittal S, Zeng J, Saul M, Kesari S, et al.
Neurooncol Adv
. 2022 Jul;
4(1):vdac096.
PMID: 35821680
Background: The genomic and overall biologic landscape of glioblastoma (GB) has become clearer over the past 2 decades, as predictive and prognostic biomarkers of both de novo and transformed forms...
5.
Stein M, Pandey M, Xiu J, Tae H, Swensen J, Mittal S, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-13.
PMID: 35100709
Purpose: Tumor mutational burden (TMB) is a developing biomarker in non-small-cell lung cancer (NSCLC). Little is known regarding differences between TMB and sample location, histology, or other biomarkers. Methods: A...
6.
Lee S, Cavaliere A, Gallezot J, Keler T, Michelhaugh S, Belitzky E, et al.
Mol Cancer Ther
. 2022 Jan;
21(3):440-447.
PMID: 35027482
There is a need for prognostic markers to select patients most likely to benefit from antibody-drug conjugate (ADC) therapy. We quantified the relationship between pretreatment PET imaging of glycoprotein nonmetastatic...
7.
Bollig-Fischer A, Bao B, Manning M, Dyson G, Michelhaugh S, Mittal S, et al.
Mol Biomed
. 2022 Jan;
2(1):26.
PMID: 35006496
The development of targeted therapies that inhibit cancer-driving oncogenes has improved outcomes of patients diagnosed with lung adenocarcinoma (LUAD). In contrast, patients diagnosed with lung squamous cell carcinoma (LUSC) suffer...
8.
Suchdev K, Kupsky W, Mittal S, Shah A
Seizure
. 2021 Nov;
93:95-101.
PMID: 34740145
Objective: new-onset refractory status epilepticus (NORSE) is defined as de novo refractory seizures occurring in previously healthy adults, without a clear underlying etiology. Due to refractory seizures and insufficient understanding...
9.
Dardis C, Donner D, Sanai N, Xiu J, Mittal S, Michelhaugh S, et al.
BMC Neurol
. 2021 Aug;
21(1):316.
PMID: 34391386
No abstract available.
10.
Singh N, Miner A, Hennis L, Mittal S
Cancer Drug Resist
. 2021 Aug;
4:17-43.
PMID: 34337348
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an exceedingly low median overall survival of only 15 months. Current standard-of-care for GBM consists of...